Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Encochleated Amphotericin B · 1 trial · 4 indications
Number of patients determined to be a Clinical Cure (resolution of the VVC signs and symptoms that were present at baseline without further antifungal treatment); Clinical Failure (incomplete resolution of signs and symptoms of VVC that were present at baseline or new signs and symptoms have developed and require the initiation of non-study antifungal drugs); or Clinical indeterminate (insufficient data are available to determine if the subject is a cure or failure)
| Arm | Type | Description |
|---|---|---|
| CAMB 200 mg | EXPERIMENTAL | 200 mg CAMB (MAT2203) Oral Amphotericin B |
| CAMB 400 mg | EXPERIMENTAL | 400 mg CAMB (MAT2203) Oral Amphotericin B |
| Fluconazole 150 mg | ACTIVE_COMPARATOR | Fluconazole Diflucan |
| Name | Type | Description |
|---|---|---|
| Oral Encochleated Amphotericin B (CAMB) | DRUG | lipid-crystal nano-particle formulation amphotericin B |
| Fluconazole | DRUG | - |
Key Inclusion Criteria: Informed consent Clinical diagnosis of moderate to severe VVC Negative pregnancy test Vaginal pH less than 4.5 Key Exclusion Criteria: Has an intolerance or hypersensitivity to any amphotericin B (AMB) product, or to azole antifungal drugs Receiving antifungal therapy ...
Encochleated Amphotericin B is an investigational small molecule being developed for the treatment of vulvovaginitis, specifically vulvovaginal candidiasis (VVC), a yeast infection of the vagina. It is an oral formulation of amphotericin B that is being studied as a potential therapy for this condition.
Encochleated Amphotericin B is an oral formulation of amphotericin B, an antifungal agent. The encochleated formulation is designed to deliver amphotericin B orally, potentially improving its absorption and tolerability compared to traditional intravenous administration. It targets fungal infections such as vulvovaginal candidiasis.
Encochleated Amphotericin B is being developed by Matinas Biopharma Holdings, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol MTNB. The company is focused on developing lipid-based formulations of drugs to improve their delivery and efficacy.
Encochleated Amphotericin B is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in treating vulvovaginal candidiasis.
Encochleated Amphotericin B has been studied in one completed Phase 2 clinical trial, identified as NCT02971007. This trial evaluated the safety and efficacy of oral encochleated amphotericin B in the treatment of vulvovaginal candidiasis. The trial enrolled 137 female participants in the United States and was actively controlled.
Yes, Encochleated Amphotericin B is also known as CAMB and MAT2203. These alternative names refer to the same investigational drug being developed by Matinas Biopharma for the treatment of vulvovaginal candidiasis.